Short-Chain Fatty Acids
Butyrate, Propionate & Acetate
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
6 human trials, about 400 studies, >5,000 participants. The written rationale for this grade is still being prepared.
- FDA
- Butyrate sold as supplement
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Direct butyrate supplements have tolerability and odor issues, and the optimal target SCFA levels in humans are not firmly established, so producing SCFAs from dietary fiber is generally the better-supported route. Human oral-supplement and enema evidence remains preliminary and mixed, and no SCFA product should be treated as a therapy for any gut, metabolic, or inflammatory condition. Ulcerative colitis, inflammatory bowel disease, and metabolic conditions require management by a qualified healthcare provider; anyone who is pregnant, nursing, treating a child, or managing a diagnosed condition should consult a qualified provider before using SCFA supplements rather than self-treating.
Short-chain fatty acids, acetate (C2), propionate (C3), and butyrate (C4), are the principal products of bacterial fiber fermentation in the colon and arguably the most important functional output of the microbiome. Butyrate is the primary energy source for the cells lining the colon, supplying the majority of their oxidative fuel, and it acts as a histone-deacetylase inhibitor and a ligand for the receptors FFAR2 and FFAR3, effects associated with a reinforced gut barrier and induction of anti-inflammatory regulatory T cells. Propionate is gluconeogenic and signals through a gut-brain circuit; acetate is the most abundant and circulates systemically. SCFA production, not raw strain count, is a more meaningful measure of what a microbiome is actually doing. The mechanism is strong; evidence that swallowing a butyrate supplement reproduces the benefit of fiber-driven, in-situ production in humans is much weaker.
The real output of the microbiome. Butyrate fuels your colon and quiets inflammation.
What it is invoked to explain
Claims this idea is used to support. Whether it supports them is the rest of the entry.
What people get wrong
Often saidMicrobiome diversity is the key metric
ActuallySCFA production, especially butyrate, is arguably the more meaningful functional readout. Wastyk and Sonnenburg (Cell, 2021) found a high-fiber diet alone did not uniformly increase microbiota diversity over ten weeks, underscoring that what the community produces can matter more than how many members it has.
Often saidButyrate is just a passive fuel molecule
ActuallyBeyond energy, butyrate is a signaling molecule. It inhibits histone deacetylases and, as shown by Furusawa et al. (Nature, 2013) and Smith et al. (Science, 2013), increases histone acetylation at the Foxp3 locus to induce anti-inflammatory colonic regulatory T cells; it also acts on the FFAR2 and FFAR3 receptors.
Often saidTaking a butyrate pill equals eating fiber
ActuallyThis is not established in humans. Human oral tributyrin and butyrate-generator pilots (e.g. the 2024 ButyraGen study) report tolerability but few significant clinical endpoints, and butyrate enema trials in ulcerative colitis are mixed. The colon makes SCFAs in situ from fiber, a route oral supplements may not reproduce.
Often saidAcetate is the important one because it is most abundant
ActuallyAbundance is not the same as function. Acetate is the most plentiful SCFA and circulates systemically, but butyrate, though less abundant, is the preferred colonocyte fuel and the strongest HDAC inhibitor, and propionate carries the main gluconeogenic and gut-brain metabolic signaling (De Vadder et al., Cell, 2013).
Who profits, and who pushes back
Microbiome metabolism researchers
Increasingly frame SCFA output, especially butyrate, as the key functional endpoint over diversity counts.
Butyrate-supplement and synbiotic brands
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market tributyrin and SCFA-boosting products; the SCFA narrative carries commercial interest.
A. Hillel Steinhart and colleagues
In a controlled trial of left-sided ulcerative colitis, once-nightly butyrate enemas produced clinical improvement in 37% of treated patients versus 47% on placebo and remission in about 16% of each group, leading the authors to conclude butyrate enemas were not efficacious in that setting.
Justin and Erica Sonnenburg (with Hannah Wastyk), Stanford
The team reported that increased fiber intake alone over a short period was insufficient to increase microbiota diversity, cautioning against assuming that simply feeding fiber, or by extension boosting SCFAs, produces uniform benefit across people.
Production-route (supplement-vs-endogenous) researchers
Whether supplemented butyrate matches fiber-driven endogenous production is unsettled; the body makes SCFAs in the colon where they are needed, and orally dosed butyrate is largely absorbed proximally, which supplements may not replicate.
Where the research comes from
| Place | Share of published research |
|---|---|
| Europe | 34% |
| USA | 30% |
| Asia | 22% |
| Other | 14% |
Research published from: Global.
How we got here
The chemistry of gut fermentation acids was studied for over a century, but the pivotal reframing came from William Roediger in Adelaide, Australia, whose 1980 work in Gut on isolated human colonocytes showed that n-butyrate, a product of anaerobic bacteria, supplies roughly three-quarters of the colon lining's oxidative fuel. That inverted the usual picture: the host cell depends on a bacterial waste product for its energy. Through the 2000s the field matured as the SCFA receptors GPR43 and GPR41 were identified in 2003 and renamed FFAR2 and FFAR3, giving SCFAs defined signaling roles. In 2013 two independent groups in Japan and the United States showed SCFAs drive colonic regulatory T cell differentiation, and a French group linked propionate to intestinal gluconeogenesis. Together this shifted the most meaningful microbiome measure from how diverse a community is to how much butyrate it makes.
- 1980Roediger (Gut) shows n-butyrate supplies ~73-75% of colonocyte oxygen consumption, naming it the primary colon-cell fuel
- 1980Roediger proposes ulcerative colitis may be an energy-deficiency state of impaired butyrate oxidation
- 1992-1997Butyrate and SCFA enema trials in distal ulcerative colitis report mixed results (Scheppach, Breuer, Steinhart)
- 2003GPR43 and GPR41 deorphanized as SCFA receptors by three independent groups; later renamed FFAR2 and FFAR3
- 2013Furusawa (Nature) and Smith (Science) show SCFAs induce colonic regulatory T cells via HDAC inhibition and Foxp3 histone acetylation
- 2013De Vadder (Cell) links propionate to intestinal gluconeogenesis through a gut-brain neural circuit
- 2010sSCFA output increasingly framed as a functional microbiome endpoint over diversity counts
- 2021Wastyk and Sonnenburg (Cell) find high-fiber diet alone does not uniformly raise diversity, sharpening focus on fermentation output
- 2020s-2024Tributyrin and butyrate-generator supplements marketed; early human pilots show tolerability but limited significant endpoints
At a glance
- Main SCFAs
- Acetate, propionate, butyrate
- Butyrate
- Primary colon-cell fuel
- Source
- Fiber fermentation
- Supplement
- Tributyrin
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Short-Chain Fatty Acids. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
n-Butyrate supplies ~73-75% of colonocyte oxygen consumption and is the primary colon-cell fuel; UC proposed as energy-deficiency state
Roediger WE, 'Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man', Gut
SCFAs (acetate, propionate, butyrate) induce colonic regulatory T cells via HDAC inhibition and histone acetylation at the Foxp3 locus
SCFAs regulate the colonic Treg pool and protect against colitis in a Ffar2 (GPR43)-dependent manner; propionate reduces HDAC6/9 and raises histone acetylation
GPR43/GPR41 deorphanized as SCFA receptors in 2003 (Brown, Le Poul, Nilsson) and renamed FFA2/FFAR2 and FFA3/FFAR3; ligand preferences by chain length
Propionate (and butyrate) activate intestinal gluconeogenesis via complementary mechanisms including a gut-brain neural circuit involving FFAR3, improving glucose homeostasis
Which colonic bacteria and pathways form butyrate and propionate (e.g. Faecalibacterium prausnitzii, Roseburia as major butyrate producers)
Butyrate is the most potent SCFA HDAC inhibitor and drives epigenetic regulation of host gene expression
High-fiber diet alone did not uniformly increase microbiota diversity over 10 weeks, sharpening focus on fermentation output over diversity counts
Oral tributyrin/butyrate-generator supplement is safe and tolerable in a human pilot but shows few significant clinical endpoints (weak human supplement evidence)
Butyrate enemas in ulcerative colitis show mixed/no benefit vs placebo in controlled trials (e.g. left-sided UC not efficacious)
Cochrane-level synthesis of SCFA/butyrate for induction of remission in ulcerative colitis (limited, mixed evidence)
PMC review, 'Short chain fatty acids (butyrate) for induction of remission in ulcerative colitis'